RxDoctor Payments Data

Vandana Duggal, MD

Family Medicine · Pleasanton, CANPI 1649449604

Payments from drug & device makers

$4,531in general payments, 2019–2025

Across 213 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Pfizer$516
  • AstraZeneca$501
  • Bayer$483
  • Novo Nordisk$425
  • Merck$176
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$4,49399%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,531 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$140,138
Medicare patients
238
Services billed
1,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$11,300
EliquisApixaban12$11,124
NamzaricMemantine Hcl/Donepezil Hcl13$7,817
SynthroidLevothyroxine Sodium51$3,926
Cyclosporine12$3,875
Levothyroxine Sodium230$2,124
Pitavastatin Calcium13$1,770
Albuterol Sulfate HfaAlbuterol Sulfate36$1,635
Atorvastatin Calcium185$1,604
Nebivolol Hcl16$1,114
Pantoprazole Sodium63$1,010
Metoprolol Succinate44$968
Gabapentin53$953
Rosuvastatin Calcium71$939
Omeprazole66$732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Synthroid$43$11,74364 claims
Novo NordiskOzempic$425$11,30012 claims
PfizerEliquis$516$11,12412 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$11$21614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Pleasanton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →